Similarly, maridebart carfraglutide, known as MariTide, a long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism, achieved 12.3–16.2% WL after 52 weeks in obese participants with slightly lower reductions in individuals with T2DM [146]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.